Evidence map›Paper›PMID 20673547›Full record

Trial reportThe Journal of clinical psychiatry2010

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.

Nancy DiazGranados, Lobna A Ibrahim, Nancy E Brutsche, Rezvan Ameli, Ioline D Henter, David A Luckenbaugh, Rodrigo Machado-Vieira, Carlos A Zarate

5 registry-linked trialsOpen access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical psychiatry, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 264 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
264citing papers in PubMed, 8 pooled it
27.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00088699 phase1 / phase2completednot on this map

Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist

TypeinterventionalSponsorNational Institute of Mental Health (NIMH)Ran2004 to 2017Enrolled67ConditionsDepression, Mood Disorders, Major DepresssionArmsKetamine, Placebo
NCT02610712 phase4unknown statusnot on this mapstarted 2014, after this paper: background citation

Clinical Trial of the Use of Ketamine in Treatment Resistant Depression

TypeinterventionalSponsorNational Institute of Neurology and Neurosurgery, MexicoRan2014Enrolled20ConditionsDepressive Disorder, Treatment-ResistantArmsKetamine
NCT03336541 phase4completednot on this mapstarted 2017, after this paper: background citation

Effects of Intraoperative Low-dose Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression Undergoing Cesarean Delivery: Blind Test, Randomized, Placebo-controlled Trial

TypeinterventionalSponsorPeking University First HospitalRan2017 to 2018Enrolled64ConditionsPerinatal Depression, Ketamine, Cesarean Delivery, Postpartum DepressionArmsKetamine, Placebo
NCT03502551 phase2withdrawnnot on this mapstarted 2019, after this paper: background citation

ED Treatment of Suicidal Patients With Ketamine Infusion

TypeinterventionalSponsorUniversity of California, DavisRan2019 to 2019Enrolled0ConditionsSuicide, Suicidal IdeationArmsKetamine
NCT03742557 phase3unknown statusnot on this mapstarted 2018, after this paper: background citation

Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation

TypeinterventionalSponsorNational Institute of Neurology and Neurosurgery, MexicoRan2018 to 2020Enrolled30ConditionsTreatment Resistant DepressionArmsKetamine 50 MG/ML Injectable Solution, 0.5 mg/kg IV
3 · Its place in the literature

Who cites it

264 citing papers in PubMed, 8 syntheses or guidelines pooled it, 559 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Entactogen Effects of Ketamine: A Reverse-Translational Study.The American journal of psychiatry · 2024
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

204 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Nancy DiazGranadosNational Institute of Mental Health, and Department of Human Health Services, Bethesda, Maryland, USA.
Lobna A Ibrahim
Nancy E Brutsche
Rezvan Ameli
Ioline D Henter
David A Luckenbaugh
Rodrigo Machado-Vieira
Carlos A Zarate
National Institutes of Health · US

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Intramural NIH HHS Z99 MH999999
6 · The paper itself

Abstract

objectiveSuicidal ideation is a medical emergency, especially when severe. Little research has been done on pharmacologic interventions that could address this problem. Ketamine, an N-methyl-D-asparate antagonist, has been reported to have antidepressant effects within hours. We examined the effects of a single dose of ketamine on suicidal ideation in subjects with treatment-resistant major depressive disorder (MDD).

methodThirty-three subjects with DSM-IV-diagnosed MDD received a single open-label infusion of ketamine (0.5 mg/kg) and were rated at baseline and at 40, 80, 120, and 230 minutes postinfusion with the Scale for Suicide Ideation (SSI), the Montgomery-Åsberg Depression Rating Scale, the Hamilton Depression Rating Scale, and the Beck Depression Inventory. The study was conducted between October 2006 and January 2009.

resultsSuicidal ideation scores decreased significantly on the SSI as well as on the suicide subscales of other rating instruments within 40 minutes; these decreases remained significant through the first 4 hours postinfusion (P < .001). Ten subjects (30%) had an SSI score ≥ 4 at baseline; all these scores dropped below 4 (9 dropped by 40 minutes and 1 by 80 minutes). For those patients with a starting score below 4 on the SSI, only 1 reached a score of 4. Depression, anxiety, and hopelessness were significantly improved at all time points (P < .001).

conclusionsSuicidal ideation in the context of MDD improved within 40 minutes of a ketamine infusion and remained improved for up to 4 hours postinfusion. Future studies with ketamine in suicidal ideation are warranted due to the potential impact on public health.

trial registrationclinicaltrials.gov Identifier: NCT00088699.

Indexed as

Suicidal IdeationAdultAntidepressive AgentsDepressionDiagnostic and Statistical Manual of Mental DisordersExcitatory Amino Acid AntagonistsFemaleHumansInfusions, IntravenousKetamineMajor Depressive DisorderMaleMiddle AgedN-MethylaspartatePsychiatric Status Rating ScalesTime FactorsAntidepressive AgentsExcitatory Amino Acid AntagonistsKetamineN-Methylaspartate

Identifiers

PMID20673547
PMCPMC3012738
OpenAlexW2103255996

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.